Clinical Management of Metastatic Colorectal Cancer

The clinical management of metastatic colorectal cancer encompasses a multidisciplinary approach that integrates systemic therapies, surgical interventions and biomarker-driven decision making. First-line treatment typically combines cytotoxic regimens—such as fluoropyrimidine-based doublets or triplets—with targeted agents selected according to tumour molecular profile, notably RAS and BRAF mutation status and microsatellite instability. Conversion strategies aim to downsize initially unresectable liver metastases through intensified chemotherapy plus biologics, thereby increasing the rate of potentially curative resections. Ongoing surveillance employs imaging and circulating biomarkers to detect progression, guide second-line therapies and monitor resistance. The advent of proteomic and genomic profiling has refined patient stratification, enabling early prediction of treatment response and individualised adjustment of monoclonal antibodies or anti-angiogenic agents. Immunotherapy has achieved durable control in selected subgroups with high microsatellite instability, while novel small-molecule inhibitors and antibody–drug conjugates are under investigation. Advances in perioperative care, including laparoscopic and ablative techniques, have reduced morbidity and improved postoperative outcomes. Collectively, this integrated model has driven progressive gains in progression-free and overall survival, affirming the importance of personalised, evidence-based management in metastatic colorectal cancer.

Research from Nature Portfolio

Recent studies have demonstrated that longitudinal plasma proteome profiling can identify distinct biomarker signatures for both initial diagnosis and ongoing assessment of cetuximab therapy response. Deep analysis of serial samples from patients undergoing anti-EGFR treatment reveals panels of proteins whose dynamic fluctuations predict treatment efficacy and emerging resistance. Predictive models built on these proteomic data offer high accuracy in forecasting individual patient trajectories across multiple courses of therapy. This work underscores the potential of blood-based assays to inform real-time treatment adaptation, enabling earlier intervention and personalised management strategies.

Clinical Management of Metastatic Colorectal Cancer publication trend

The graph below shows the total number of articles in clinical management of metastatic colorectal cancer across all publications each year (not limited to Nature Index journals).

Technical terms

Metastasis: The spread of cancer cells from the primary tumour to distant organs, forming secondary growths.

Progression-Free Survival: The length of time during and after treatment that a patient lives without disease progression.

Overall Survival: The time from diagnosis or start of treatment until death from any cause.

Biomarker: A measurable indicator, such as a protein or gene mutation, used to assess disease state or treatment response.

Proteomic Profiling: Large-scale analysis of the complete set of proteins in a biological sample to identify patterns linked to disease or therapy outcome.

Cetuximab: A monoclonal antibody targeting the epidermal growth factor receptor to inhibit tumour growth in RAS-wild-type colorectal cancer.

RAS Mutation: Alterations in RAS genes that can drive tumour proliferation and predict resistance to certain targeted therapies.

References

1. Longitudinal plasma proteome profiling reveals the diversity of biomarkers for diagnosis and cetuximab therapy response of colorectal cancer. Nature Communications (2024).
2. Metastatic Colorectal Cancer. First Line Therapy for Unresectable Disease. Journal of Clinical Medicine (2020).
3. Conversion strategies with chemotherapy plus targeted agents for colorectal cancer liver-only metastases: A systematic review. European Journal of Cancer (2020).
4. Survival improvement for patients with metastatic colorectal cancer over twenty years. npj Precision Oncology (2023).